Authors:
Immuno-oncology (IO) therapies, pembrolizumab and nivolumab, were approved in 2016 as single agents for the treatment of R/M HNSCC with disease progression on or after platinum-based chemotherapy (PbC) in the US. We examined treatment patterns and estimated real-world time on treatment (rwToT) with IO and non-IO based therapies post-PbC in patients with R/M HNSCC.
Sources:
Future Medicine